United States Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) and Good Manufacturing Practice (GMP) inspection at Bliss GVS Pharma’s manufacturing unit at Dewan Udyog Nagar, Aliyali Village, Palghar, Maharashtra from March 13, 2023 to March 17, 2023. After the inspection, the USFDA issued a Form 483 with 3 minor observations.
The observations are procedural in nature. The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.
Bliss GVS Pharma is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market.
